In:
Clinical and Applied Thrombosis/Hemostasis, SAGE Publications, Vol. 28 ( 2022-01), p. 107602962211233-
Kurzfassung:
Direct oral anticoagulants (DOACs) have increasingly become an alternative to warfarin in atrial fibrillation (AF) patients. Nonetheless, data on the effectiveness and safety of DOACs in periprocedural of catheter ablation (CA) in real-world practice was relatively rare. Methods and Results 3385 AF patients underwent initial CA and never used oral anticoagulant before enrollment between April 2013 and December 2018 were involved from China Atrial Fibrillation (China-AF) Registry. Warfarin, rivaroxaban and dabigatran were used in 1896 (56.0%), 718 (21.2%), and 771 (22.8%) patients, respectively. Propensity score matching was used to balance covariates across study groups. No significant differences were observed in rivaroxaban-warfarin, dabigatran-warfarin and dabigatran-rivaroxaban cohort for thromboembolic (TE) and major bleeding (MB) incidence. Similar results were also revealed in low-dose rivaroxaban (R LD )-warfarin, low-dose dabigatran (D LD )-warfarin and D LD -R LD cohort. However, the risk of non-MB was higher not only on standard-dose of rivaroxaban but also on R LD when compared with warfarin and with D LD , respectively. Conclusions In this study, the incidence of TE and MB were both comparable in standard- or low-dose DOACs versus warfarin and between the two DOACs, whereas the risk of non-MB was higher in rivaroxaban than in warfarin and in R LD than in D LD .
Materialart:
Online-Ressource
ISSN:
1076-0296
,
1938-2723
DOI:
10.1177/10760296221123306
Sprache:
Englisch
Verlag:
SAGE Publications
Publikationsdatum:
2022
ZDB Id:
2230591-9
